Search research articles
Contact Us
Filters
Showing results (821-830 of 1,095) with videos related to
Page
of 110
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation
|
February 16, 2023
Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation
Paolo Angelo Cortesi, Raffaella Viganò, Sara Conti, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
International Journal of Emergency Medicine
|
January 4, 2024
Emergency department contribution to HCV elimination in the Iberian Peninsula
Maria Buti, Inês Vaz-Pinto, Vítor Magno Pereira, et al.
International Journal of Molecular Sciences
|
December 11, 2022
Quasispecies Fitness Partition to Characterize the Molecular Status of a Viral Population. Negative Effect of Early Ribavirin Discontinuation in a Chronically Infected HEV Patient
Josep Gregori, Sergi Colomer-Castell, Carolina Campos, et al.
Hepatology (Baltimore, Md.)
|
November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Immunotherapy
|
August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Journal of Clinical Microbiology
|
November 8, 2019
Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?
Rosa López-Martínez, Andrea Arias-García, Francisco Rodríguez-Algarra, et al.
Immunotherapy
|
March 23, 2018
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Page
of 110
Search research articles
Search
Showing results (821-830 of 1,095) with videos related to
Sort By:
Page
of 110
Transplant International : Official Journal of the European Society for Organ Transplantation
|
February 16, 2023
Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation
Paolo Angelo Cortesi, Raffaella Viganò, Sara Conti, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
International Journal of Emergency Medicine
|
January 4, 2024
Emergency department contribution to HCV elimination in the Iberian Peninsula
Maria Buti, Inês Vaz-Pinto, Vítor Magno Pereira, et al.
International Journal of Molecular Sciences
|
December 11, 2022
Quasispecies Fitness Partition to Characterize the Molecular Status of a Viral Population. Negative Effect of Early Ribavirin Discontinuation in a Chronically Infected HEV Patient
Josep Gregori, Sergi Colomer-Castell, Carolina Campos, et al.
Hepatology (Baltimore, Md.)
|
November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Immunotherapy
|
August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Journal of Clinical Microbiology
|
November 8, 2019
Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?
Rosa López-Martínez, Andrea Arias-García, Francisco Rodríguez-Algarra, et al.
Immunotherapy
|
March 23, 2018
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Page
of 110